Chosen to establish program in robotic general and gynecologic surgery
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is
pioneering the use of robotics to improve minimally invasive surgery,
today announced that the Company has launched commercial operations and
completed its first sale of the Senhance Surgical System in Germany.
St. Marien-Krankenhaus Siegen, a large multi-specialty hospital, has
purchased the Senhance Surgical System to establish a robotic surgical
program that will initially be focused on general and gynecologic
"We chose the Senhance to bring robotic surgical assistance to the
treatment of our patients," said Professor Dr. Frank Willeke, Medical
Director of St. Marien. "The combination of robotic precision, advanced
visualization, and haptic technology are important to further offering
the best minimally invasive surgery to our patients and was particularly
compelling to our surgical leadership under the supervision of Dr.
Dietmar Stephan. The Senhance system also allows our hospital to offer
the latest technology at a reasonable cost."
"St. Marien Hospital in Siegen chose the Senhance because of our unique
combination of advanced technology and responsible economics," said Todd
M. Pope, President and CEO of TransEnterix. "We have been focused on
growing our capabilities to sell to and support hospitals in Germany, a
critical market for our company, and are pleased to partner with one of
Germany's leading centers for minimally invasive surgery."
St. Marien is part of an independent, integrated health group that
treats patients throughout the federal states of North Rhine-Westphalia
and Rhineland-Palatinate. For more information, please visit www.marienkrankenhaus.com.
TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options. The company is focused on the commercialization of
the Senhance Surgical Robotic System, a multi-port robotic system that
brings the advantages of robotic surgery to patients while enabling
surgeons with innovative technology such as haptic feedback and eye
sensing camera control. The company is also developing the SurgiBot™
System, a single-port, robotically enhanced laparoscopic surgical
platform. The Senhance Surgical Robotic System has been granted a CE
Mark but is not currently available for sale in the United States. For
more information, visit the TransEnterix website at www.transenterix.com.
This press release includes statements relating to the Senhance™
Surgical Robotic System and our current regulatory and commercialization
plans for this product. These statements and other statements regarding
our future plans and goals constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are subject to
risks and uncertainties that are often difficult to predict, are beyond
our control and which may cause results to differ materially from
expectations and include whether the Senhance System uses a unique
combination of advanced technology and responsible economics. For a
discussion of the risks and uncertainties associated with TransEnterix's
business, please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K filed on
March 3, 2016 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of this
press release and speak only as of the origination date of this
press release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new information,
future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170223005663/en/
For TransEnterix, Inc.
(For EU) Conrad Harrington, +44 (0)20 3178 8914
US) Hannah Dunning, +1 415-618-8750
Source: TransEnterix, Inc.
News Provided by Acquire Media